Noile-Immune Biotech Inc. (JP:4893)

:4893

4893

Noile-Immune Biotech Inc.

RESEARCH TOOLSreports

Noile-Immune Biotech Inc. (4893) Price & Analysis

Compare

0 Followers

4893 Stock Chart & Stats

¥134.00

¥9.00(4.81%)

At close: Jan 08 4:00 PM EST

¥134.00

¥9.00(4.81%)

Day’s Range― - ―

52-Week Range¥120.00 - ¥217.00

Previous CloseN/A

Volume1.93M

Average Volume (3M)85.17K

Market Cap

¥6.53B

Enterprise Value¥2.62B

Total Cash (Recent Filing)¥4.31B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.45

Next Earnings

May 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.36

Shares Outstanding43,276,764

10 Day Avg. Volume110,290

30 Day Avg. Volume85,173

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.46

Price to Sales (P/S)1151.82

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-34

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free capital structure materially reduces solvency risk and interest burden over the medium term, giving management flexibility to fund R&D or pursue partnerships without immediate debt servicing constraints. This durability supports runway and strategic optionality before commercialization.

Very High Gross MarginsNear-100% gross margins imply attractive unit economics for productized therapies: once fixed development costs are covered, revenue can drop straight to operating leverage. This structural margin profile supports high long-term profitability if clinical and commercial scale are achieved.

Platform Focus In Cell-based ImmunotherapiesA platform centered on engineered immune-cell products targets a sustained, high-growth therapeutic area with structural demand (oncology/immune diseases). Platform tech can create multiple candidates or licensing opportunities, offering durable upside if clinical validation or partner deals occur.

Bears Say

Sharply Shrinking RevenueA steep, persistent decline in revenue undermines operating leverage and suggests troubles in commercialization, partnerships, or product demand. Over 2-6 months this reduces funding flexibility, makes R&D prioritization harder, and raises the bar for achieving sustainable profitability.

Persistent Negative Operating Cash FlowConsistent negative operating cash flow forces reliance on external financing or equity dilution to sustain R&D and trials. Even with some improvement, ongoing cash burn is a structural financing risk that can limit strategic initiatives and increase dilution pressure until revenue generation is stable.

Large Net Losses And Negative Returns On EquitySustained large losses and negative ROE signal shareholder capital is not generating positive returns. Over months this erodes equity, constrains reinvestment capacity, and heightens the need for successful clinical milestones or partner funding to reverse value destruction trends.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥120.00 and its highest was ¥217.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥6.53B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is May 19, 2026 which is in 51 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on Feb 13, 2026. The company reported -¥4.36 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.36.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,276,764 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥4.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.938%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.